MX2020007384A - Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado. - Google Patents

Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.

Info

Publication number
MX2020007384A
MX2020007384A MX2020007384A MX2020007384A MX2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A
Authority
MX
Mexico
Prior art keywords
hepatitis
liver disease
methods
inflammatory liver
treating diabetes
Prior art date
Application number
MX2020007384A
Other languages
English (en)
Inventor
Michael A Lynes
Yu-Hua Tseng
Matthew D Lynes
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of MX2020007384A publication Critical patent/MX2020007384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente descripción se describen usos del inhibidor de la metalotioneína humana extracelular (MT) para tratar un trastorno seleccionado del grupo que consiste en diabetes, prediabetes, tolerancia a la glucosa alterada, hepatitis y/o enfermedad inflamatoria del hígado, y composiciones que contienen MT humana extracelular.
MX2020007384A 2018-01-17 2019-01-17 Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado. MX2020007384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
MX2020007384A true MX2020007384A (es) 2020-10-19

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007384A MX2020007384A (es) 2018-01-17 2019-01-17 Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.

Country Status (14)

Country Link
US (3) US11866488B2 (es)
EP (1) EP3740282A1 (es)
JP (2) JP7486423B2 (es)
KR (1) KR20200110659A (es)
CN (1) CN111801140A (es)
AU (2) AU2019209491B2 (es)
BR (1) BR112020014346A2 (es)
CA (1) CA3088661A1 (es)
EA (1) EA202091533A1 (es)
IL (1) IL276097A (es)
MX (1) MX2020007384A (es)
PH (1) PH12020551076A1 (es)
SG (1) SG11202006421RA (es)
WO (1) WO2019143767A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220306731A1 (en) 2019-07-15 2022-09-29 University Of Connecticut Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) * 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
WO2011050052A2 (en) * 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
BR112013007850A2 (pt) 2010-10-14 2016-06-07 Immunahr Ab 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr
CA2840282C (en) 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
AU2015268101B2 (en) * 2014-05-27 2021-01-28 The University Of Queensland Modulation of cellular stress
US9487783B2 (en) 2014-08-07 2016-11-08 Regulus Therapeutics Inc. Targeting microRNAs for metabolic disorders

Also Published As

Publication number Publication date
EP3740282A1 (en) 2020-11-25
PH12020551076A1 (en) 2021-08-16
SG11202006421RA (en) 2020-08-28
CA3088661A1 (en) 2019-07-25
KR20200110659A (ko) 2020-09-24
AU2019209491A1 (en) 2020-07-23
CN111801140A (zh) 2020-10-20
AU2019209491B2 (en) 2022-05-19
US20240067710A1 (en) 2024-02-29
BR112020014346A2 (pt) 2020-12-08
US20240025981A1 (en) 2024-01-25
IL276097A (en) 2020-08-31
US20200369757A1 (en) 2020-11-26
JP2024028454A (ja) 2024-03-04
AU2022215285B2 (en) 2024-08-29
JP7486423B2 (ja) 2024-05-17
WO2019143767A1 (en) 2019-07-25
EA202091533A1 (ru) 2020-11-16
AU2022215285A1 (en) 2022-09-29
JP2021511296A (ja) 2021-05-06
US11866488B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
MX2020007092A (es) Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
MX2020008271A (es) Inhibidor de fap.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
BR112017024684A2 (pt) compostos coagonistas de glucagon e glp-1
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
MX2020010369A (es) Particulas implantables y metodos relacionados.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201170349A1 (ru) Модуляторы mif
TW200716612A (en) Pyrimidine compounds
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CR20210460A (es) Compuestos útiles en la terapia del vih
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
TW200719903A (en) Compositions for the treatment of neoplasms
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MY196680A (en) Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer